{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:40:36Z","timestamp":1791812436756,"version":"4.3.4"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0101848","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T17:20:28Z","timestamp":1405099228000},"page":"e101848","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":83,"title":["Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients"],"prefix":"10.1371","volume":"9","author":[{"given":"Cesarina","family":"Giallongo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunziatina","family":"Parrinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tibullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"La Cava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1470-2045(11)70228-5","article-title":"First-line therapy for CML: nilotinib comes of age","volume":"12","author":"J Davies","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"S Bose","year":"1998","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138945011794815301","article-title":"Interferon alpha for treatment of chronic myeloid leukemia","volume":"12","author":"B Simonsson","year":"2011","journal-title":"Curr Drug Targets"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"C Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/10428190290021687","article-title":"Chronic phase CML patients possess T cells capable of recognising autologous tumour cells","volume":"43","author":"L Muller","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"ref8","first-page":"1931","article-title":"Differential recognition of a BCR\/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients","volume":"6","author":"C Bertazzoli","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref9","first-page":"817","article-title":"Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis","volume":"111","author":"X Chen","year":"2000","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002620050270","article-title":"Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro","volume":"42","author":"G Pawelec","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"KW Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00262-011-1161-9","article-title":"Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients","volume":"61","author":"P Filipazzi","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"DI Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","article-title":"Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression","volume":"16","author":"P Serafini","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"K Movahedi","year":"2008","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clim.2012.06.003","article-title":"On the armament and appearances of human myeloid-derived suppressor cells","volume":"144","author":"I Poschke","year":"2012","journal-title":"Clin Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1349-7006.2012.02248.x","article-title":"Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck","volume":"103","author":"K Chikamatsu","year":"2012","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00262-011-1116-1","article-title":"A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells","volume":"61","author":"A Thakur","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-60761-869-0_12","article-title":"Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation","volume":"677","author":"N Van Rompaey","year":"2011","journal-title":"Methods Mol Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"V Bronte","year":"2003","journal-title":"Trends Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"B Huang","year":"2006","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2004-07-2521","article-title":"Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity","volume":"105","author":"M Munder","year":"2005","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, <etal>et al<\/etal>.. (2012) Nuclear translocation of heme oxygenase-1 confers resistance to Imatinib in chronic myeloid leukemia cells. Curr Pharm Des.","DOI":"10.2174\/1381612811319150012"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2119\/molmed.2011.00278","article-title":"Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetalloproteinase-2 and -9","volume":"18","author":"K Zitta","year":"2012","journal-title":"Mol Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1479-5876-9-90","article-title":"Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines","volume":"9","author":"MG Lechner","year":"2011","journal-title":"J Transl Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/imm.12004","article-title":"Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability","volume":"137","author":"BD Hock","year":"2012","journal-title":"Immunology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2012.04.004","article-title":"Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples","volume":"381","author":"A Kotsakis","year":"2012","journal-title":"J Immunol Methods"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"V Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1189\/jlb.1109737","article-title":"Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation","volume":"89","author":"R Rotondo","year":"2011","journal-title":"J Leukoc Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","article-title":"Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate","volume":"153","author":"E Bachy","year":"2011","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1\/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia","volume":"8","author":"L Christiansson","year":"2013","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"X Chen","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"PY Pan","year":"2010","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.exphem.2010.09.004","article-title":"Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive","volume":"38","author":"JM Rojas","year":"2010","journal-title":"Exp Hematol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5603\/FHC.2011.0022","article-title":"Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"49","author":"I Hus","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine","volume":"96","author":"UH Mellqvist","year":"2000","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","article-title":"Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration","volume":"101","author":"R Dong","year":"2003","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","author":"M Munder","year":"2006","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.24448","article-title":"IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer","volume":"125","author":"R Rotondo","year":"2009","journal-title":"Int J Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e18534","DOI":"10.1371\/journal.pone.0018534","article-title":"Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1","volume":"6","author":"KC Boelte","year":"2011","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"J Finke","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ncb1507","article-title":"Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis","volume":"8","author":"S Hiratsuka","year":"2006","journal-title":"Nat Cell Biol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/1541-7786.MCR-10-0394","article-title":"S100A8\/A9 activate key genes and pathways in colon tumor progression","volume":"9","author":"M Ichikawa","year":"2011","journal-title":"Mol Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"T Condamine","year":"2011","journal-title":"Trends Immunol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0b013e318242169f","article-title":"Myeloid-derived suppressor cells in cancer patients: a clinical perspective","volume":"35","author":"AJ Montero","year":"2012","journal-title":"J Immunother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","article-title":"Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology","volume":"61","author":"CA Dumitru","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2013.02.007","article-title":"The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?","volume":"23","author":"S Brandau","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"DM Ross","year":"2013","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2141.2011.08939.x","article-title":"Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib","volume":"157","author":"K Ohyashiki","year":"2012","journal-title":"Br J Haematol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0101848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T06:20:37Z","timestamp":1598077237000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0101848"}},"subtitle":[],"editor":[{"given":"Giovanni Li","family":"Volti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":51,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0101848","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]}}}